Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial - Takeaways - MDSpire

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial

  • By

  • Keith J Chappell

  • Francesca L Mordant

  • Alberto A Amarilla

  • Naphak Modhiran

  • Benjamin Liang

  • Zheyi Li

  • Julia A Lackenby

  • Noushin Jaberolansar

  • Jake O’Donnell

  • Vivian Kienzle

  • Varsha Kommajosyula

  • Nicolas Tardiota

  • Jillian K Bennet

  • Christina L Henderson

  • Rhiannon L Dalrymple

  • Justin Goh

  • Kym Hoger

  • Marianne Gillard

  • Martina L Jones

  • Karen Hughes

  • Ben Hughes

  • James Barnes

  • Patrick C Reading

  • Charani Ranasinghe

  • Kanta Subbarao

  • Trent P Munro

  • Paul R Young

  • Daniel Watterson

  • November 25, 2025

  • 0 min

Share

  • 1

    The study evaluated the safety and immune response of the UQSC2 SARS-CoV-2 spike subunit vaccine using a second-generation molecular clamp.

  • 2

    A phase I, double-blind trial involved 70 healthy adults aged 18-50 who received a booster dose of either UQSC2 or NVX-CoV2373.

  • 3

    Both UQSC2 and NVX-CoV2373 were well tolerated and elicited comparable increases in neutralizing humoral responses against SARS-CoV-2.

  • 4

    The MC2 platform demonstrated potential for rapid vaccine development against emerging variants of SARS-CoV-2 and other respiratory viruses.

  • 5

    The trial's findings support the effectiveness of the MC2 platform in producing vaccines without interfering with HIV-1 diagnostic tests.

Original Source(s)

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial

  • by Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Julia A Lackenby, Noushin Jaberolansar, Jake O’Donnell, Vivian Kienzle, Varsha Kommajosyula, Nicolas Tardiota, Jillian K Bennet, Christina L Henderson, Rhiannon L Dalrymple, Justin Goh, Kym Hoger, Marianne Gillard, Martina L Jones, Karen Hughes, Ben Hughes, James Barnes, Patrick C Reading, Charani Ranasinghe, Kanta Subbarao, Trent P Munro, Paul R Young, Daniel Watterson

  • November 25, 2025

Related Content

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study

Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave